These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Evolution in the pharmacological treatment of venous thrombosis according to evidence-based medicine]. Manganaro A; Giannino D; Lembo D; Bruni F; Consolo F Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):41-51. PubMed ID: 11253339 [TBL] [Abstract][Full Text] [Related]
7. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice]. Ottani F; Ferrini D; Di Pasquale G; Galvani M Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833 [TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? Kaul S; Shah PK J Am Coll Cardiol; 2000 Jun; 35(7):1699-712. PubMed ID: 10841215 [TBL] [Abstract][Full Text] [Related]
9. Effective use of fondaparinux in patient with unresponsiveness to nadroparin. Hartinger JM; Svobodová A; Malíková I; Šachl R; Slanař O J Clin Pharm Ther; 2021 Apr; 46(2):539-542. PubMed ID: 33277918 [TBL] [Abstract][Full Text] [Related]
10. Therapy of unstable angina with the low molecular weight heparins. Ageno W; Turpie AG Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233 [TBL] [Abstract][Full Text] [Related]
11. High plasma endostatin level unaffected by low-molecular weight heparin in hemodialysis patients--a preliminary report. Rydzewska-Rosolowska A; Borawski J; Mysliwiec M Adv Med Sci; 2009; 54(2):199-202. PubMed ID: 19758969 [TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Couturaud F; Julian JA; Kearon C Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355 [TBL] [Abstract][Full Text] [Related]
13. The role of low-molecular-weight heparin in the management of acute coronary syndromes. Cohen M Curr Opin Cardiol; 2001 Nov; 16(6):384-9. PubMed ID: 11704710 [TBL] [Abstract][Full Text] [Related]
16. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases. Pineo GF; Hull RD Eur J Med Res; 2004 Apr; 9(4):215-24. PubMed ID: 15210402 [TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparins in acute coronary syndrome. Creekmore F S D J Med; 2000 Jan; 53(1):21-3. PubMed ID: 10652862 [No Abstract] [Full Text] [Related]
18. Dalteparin: new indication. Prophylaxis in medical patients: no advance. Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168 [TBL] [Abstract][Full Text] [Related]
19. Impact of perioperative low-molecular-weight heparin therapy on clinical events of elderly patients with prior coronary stents implanted > 12 months undergoing non-cardiac surgery: a randomized, placebo-controlled trial. Wang B; Su Y; Ma C; Xu L; Mao Q; Cheng W; Lu Q; Zhang Y; Wang R; Lu Y; He J; Chen S; Chen L; Li T; Gao L BMC Med; 2024 Apr; 22(1):171. PubMed ID: 38649992 [TBL] [Abstract][Full Text] [Related]
20. [Heparin in the treatment of unstable angina. Can the decrease of the molecular size increase its effectiveness?]. Panchenko EP Ter Arkh; 1998; 70(12):71-4. PubMed ID: 10067259 [No Abstract] [Full Text] [Related] [Next] [New Search]